Cloud Banner
Home Pharmaceutical global-primary-angle-closure-glaucoma-market

Pharmaceutical

Image

Global Primary Angle-Closure Glaucoma Market – Industry Trends and Forecast to 2028

  • Pharmaceutical
  • Published Report
  • Mar 2021
  • Global
  • 350 Pages
  • No of Tables: 375
  • No of Figures: 66

Global Primary Angle-Closure Glaucoma Market, By Disease Type (Acute Angle-Closure Glaucoma and Chronic Angle-Closure Glaucoma), Type (Diagnosis and Treatment), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (U.S., Canada, Mexico, Germany, France, Italy U.K., Spain, Russia, Austria, Netherlands, Hungary, Poland, Switzerland, Turkey, Norway, Lithuania, Ireland, Rest of Europe, Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Egypt, Saudi Arabia, Israel, UAE, Kuwait, Rest of Middle East and Africa) Industry Trends and Forecast to 2028

Primary Angle-Closure Glaucoma Market

Market Analysis and Insights: Global Primary Angle-Closure Glaucoma Market

The primary angle-closure glaucoma market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.1% in the forecast period of 2021 to 2028 and is expected to reach USD 340.82 million by 2028. Increasing prevalence of angle-closure glaucoma and advancement in surgical treatment of the disease are the key drivers for global primary angle-closure glaucoma market.

Glaucoma is a group of eye conditions that damage the optic nerve and the proper functioning of the optic nerve is necessary for good vision. This damage is often caused by abnormally high pressure in the eye. The primary angle-closure (PAC) is defined as appositional or synechial closure of the anterior chamber angle which can lead to aqueous outflow obstruction and raised IOP in the absence of glaucomatous optic neuropathy.

The increasing population of women globally and greater female to male ratio in angle-closure glaucoma due to various anatomical and hormonal factors showed the prevalence of the disease in women with increasing women population which is expected to drive the primary angle-closure glaucoma market in the forecasted period. The poor reimbursements are seen as a restraint for the primary angle-closure glaucoma market. The governing body for the approval of products has a significant role in the primary angle-closure glaucoma market growth. The increasing approval of the product for the primary angle-closure glaucoma is expected to boost the market in the forecasted period and will act as opportunities for the primary angle-closure glaucoma market growth. The risks associated with the micro-invasive glaucoma surgery acts as a challenge for the primary angle-closure glaucoma market.   

The primary angle-closure glaucoma market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the primary angle-closure glaucoma market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.  

Primary Angle-Closure Glaucoma Market

Primary Angle-Closure Glaucoma Market Scope and Market Size 

The primary angle-closure glaucoma market is segmented on the basis of the disease type, type, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of disease type, the primary angle-closure glaucoma market is segmented into acute angle-closure glaucoma and chronic angle-closure glaucoma. In 2021, acute angle-closure glaucoma segment is dominating in the primary angle-closure glaucoma market owing to the high incidence cases for acute cases.

  • On the basis of type, the primary angle-closure glaucoma market is segmented into diagnosis and treatment. In 2021, diagnosis segment is dominating in the primary angle-closure glaucoma market due to the primary test and secondary testing options available for the diagnosis and physicians after a proper diagnosis only prefer the medical procedure.

  • On the basis of end user, the primary angle-closure glaucoma market is segmented into hospitals, specialty clinics, ambulatory surgical centers and others. In 2021, hospitals segment is dominating the primary angle-closure glaucoma market as this segment is specialized in conducting various surgical interventions and has a large professional’s portfolio available for giving the proper treatment.

  • On the basis of distribution channel, the primary angle-closure glaucoma market is segmented into direct tender, retail sales and others. In 2021, direct tender segment dominates the primary angle-closure glaucoma market as they are the primary source of procurement of diagnostic and surgical devices by healthcare organizations and specialty clinics.

Primary Angle-Closure Glaucoma Market

Global Primary Angle-closure Glaucoma Market Country Level Analysis

Global primary angle-closure glaucoma market is analysed and market size information is provided by the country, disease type, type, end user and distribution channel as referenced above.

The countries covered in the global primary angle-closure glaucoma market report are the U.S., Canada, Mexico, Germany, France, Italy U.K., Spain, Russia, Austria, Netherlands, Hungary, Poland, Switzerland, Turkey, Norway, Lithuania, Ireland, rest of Europe, Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, South Africa, Egypt, Saudi Arabia, Israel, UAE, Kuwait and rest of Middle East and Africa.

North America is expected to dominate the primary angle-closure glaucoma market due to the presence of the largest consumer market with high GDP. The U.S. has the highest household spending in the world and higher diagnosis segment as well as treatment rate making it the largest market for primary angle-closure glaucoma products. Europe is expected to grow with the highest CAGR in the forecasted period due to several studies being conducted in the Germany along with superior healthcare facilities for the diagnosis segment. Asia-Pacific is expected to grow with the most promising growth rate in the forecast period of 2020 to 2028 with changing lifestyle and growing urbanization. Japan is expected to dominate in the market in the Asia-Pacific as Japan is one of the leading countries in the world with rapidly increasing product usage and diagnosis segment rate with rising awareness regarding primary angle-closure glaucoma. Middle East and Africa is expected to grow with the substantial growth rate in the forecast period of 2020 to 2028 as Middle East and Africa counties has rising awareness regarding the target disease in the region.   

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.  

Strategic Initiatives by Manufacturers is Creating New Opportunities for Players in the Primary Angle-Closure Glaucoma Market 

The primary angle-closure glaucoma market also provides you with detailed market analysis for every country growth in aesthetic industry with primary angle-closure glaucoma product sales, impact of advancement in the primary angle-closure glaucoma and changes in regulatory scenarios with their support for the primary angle-closure glaucoma market. The data is available for historic period 2011 to 2019.  

Competitive Landscape and Primary Angle-Closure Glaucoma Market Share Analysis

The primary angle-closure glaucoma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to global primary angle-closure glaucoma market.

The major companies dealing in the global primary angle-closure glaucoma market report are Johnson & Johnson Vision Care, Inc. (a subsidiary of Johnson & Johnson Services Inc.), Aurolab, New World Medical, Inc., Sight Sciences, Inc., NIDEK CO., LTD, BVI, MicroSurgical Technology, Allergan (a subsidiary of AbbVie Inc.), Bausch & Lomb Incorporated (a subsidiary of Bausch Health Companies Inc.), Oertli Instrumente AG, Medisonic Equipments Pvt. Ltd., Omni Lens, APPASAMY ASSOCIATES, NOVAEYE MEDICAL, ZEISS International, Alcon Inc., LIGHTMED, Luneau Technology USA, Reichert, Inc. (a business unit of Ametek Inc.) and NEW VISION among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launches and agreements are also initiated by the companies’ worldwide which are also accelerating the primary angle-closure glaucoma market.

For instance, 

  • In June 2020, Johnson & Johnson Vision Care, Inc. has announced to donate to Optometry Cares – The American Optometric Association (AOA) Foundation and the American Academy of Optometry Foundation. The total amount of USD 0.30 million were donated by the company for the practitioner in their support to provide eye care to the community affected by COVID-19.

Collaboration, joint ventures and other strategies by the market players is enhancing the company market in the primary angle-closure glaucoma which also provides the benefits for organisations to improve their offerings for primary angle-closure glaucoma market.    

 

 

SKU-

TABLE 1 GLOBAL PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, PIPELINE ANALYSIS

TABLE 2 NUMBER OF OPHTHALMOLOGISTS/MILLION POPULATIONS

TABLE 3 GLOBAL PRIMARY ANGLE CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 4 GLOBAL ACUTE-ANGLE CLOSURE GLAUCOMA IN PRIMARY ANGLE CLOSURE GLAUCOMA MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 GLOBAL CHRONIC ANGLE-CLOSURE GLAUCOMA IN PRIMARY ANGLE CLOSURE GLAUCOMA MARKET,BY REGION, 2019-2028 (USD MILLION)

TABLE 6 GLOBAL PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 7 GLOBAL DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 8 GLOBAL DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 9 GLOBAL PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 10 GLOBAL SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 11 GLOBAL TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE 2019-2028 (USD MILLION)

TABLE 12 GLOBAL TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 13 GLOBAL PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 14 GLOBAL HOSPITALS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 15 GLOBAL AMBULATORY SURGICAL CENTERS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 16 GLOBAL SPECIALTY CLINICS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 17 GLOBAL OTHERS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 18 GLOBAL PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 19 GLOBAL DIRECT TENDER IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 20 GLOBAL RETAIL SALES IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 21 GLOBAL OTHERS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 22 GLOBAL PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 NORTH AMERICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 24 NORTH AMERICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 25 NORTH AMERICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 26 NORTH AMERICA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 27 NORTH AMERICA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 28 NORTH AMERICA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 29 NORTH AMERICA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 30 NORTH AMERICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 31 NORTH AMERICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 32 U.S. PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 33 U.S. PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 34 U.S. DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 35 U.S. PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 36 U.S. SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 37 U.S. TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 38 U.S. PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 39 U.S. PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 40 CANADA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 41 CANADA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 42 CANADA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 43 CANADA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 44 CANADA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 45 CANADA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 46 CANADA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 47 CANADA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 48 MEXICO PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 49 MEXICO PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 50 MEXICO DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 51 MEXICO PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 52 MEXICO SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 53 MEXICO TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 54 MEXICO PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 55 MEXICO PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 56 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 57 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 58 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 59 EUROPE DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 60 EUROPE PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 61 EUROPE SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 62 EUROPE TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 63 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 64 EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 65 GERMANY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 66 GERMANY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 67 GERMANY DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 68 GERMANY PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 69 GERMANY SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 70 GERMANY TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 71 GERMANY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 72 GERMANY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 73 FRANCE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 74 FRANCE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 75 FRANCE DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 76 FRANCE PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 77 FRANCE SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 78 FRANCE TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 79 FRANCE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 80 FRANCE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 81 ITALY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 82 ITALY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 83 ITALY DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 84 ITALY PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 85 ITALY SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 86 ITALY TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 87 ITALY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 88 ITALY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 89 U.K. PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 90 U.K. PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 91 U.K. DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 92 U.K. PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 93 U.K. SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 94 U.K. TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 95 U.K. PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 96 U.K. PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 97 SPAIN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 98 SPAIN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 99 SPAIN DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 100 SPAIN PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 101 SPAIN SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 102 SPAIN TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 103 SPAIN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 104 SPAIN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 105 RUSSIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 106 RUSSIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 107 RUSSIA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 108 RUSSIA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 109 RUSSIA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 110 RUSSIA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 111 RUSSIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 112 RUSSIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 113 AUSTRIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 114 AUSTRIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 115 AUSTRIA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 116 AUSTRIA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 117 AUSTRIA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 118 AUSTRIA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 119 AUSTRIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 120 AUSTRIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 121 NETHERLANDS PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 122 NETHERLANDS PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 123 NETHERLANDS DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 124 NETHERLANDS PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 125 NETHERLANDS SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 126 NETHERLANDS TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 127 NETHERLANDS PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 128 NETHERLANDS PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 129 HUNGARY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 130 HUNGARY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 131 HUNGARY DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 132 HUNGARY PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 133 HUNGARY SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 134 HUNGARY TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 135 HUNGARY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 136 HUNGARY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 137 POLAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 138 POLAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 139 POLAND DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 140 POLAND PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 141 POLAND SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 142 POLAND TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 143 POLAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 144 POLAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 145 SWITZERLAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 146 SWITZERLAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 147 SWITZERLAND DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 148 SWITZERLAND PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 149 SWITZERLAND SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 150 SWITZERLAND TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 151 SWITZERLAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 152 SWITZERLAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 153 TURKEY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 154 TURKEY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 155 TURKEY DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 156 TURKEY PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 157 TURKEY SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 158 TURKEY TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 159 TURKEY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 160 TURKEY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 161 NORWAY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 162 NORWAY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 163 NORWAY DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 164 NORWAY PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 165 NORWAY SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 166 NORWAY TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 167 NORWAY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 168 NORWAY PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 169 LITHUANIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 170 LITHUANIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 171 LITHUANIA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 172 LITHUANIA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 173 LITHUANIA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 174 LITHUANIA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 175 LITHUANIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 176 LITHUANIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 177 IRELAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 178 IRELAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 179 IRELAND DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 180 IRELAND PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 181 IRELAND SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 182 IRELAND TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 183 IRELAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 184 IRELAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 185 REST OF EUROPE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 186 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 187 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 188 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 189 ASIA-PACIFIC DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 190 ASIA-PACIFIC PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 191 ASIA-PACIFIC SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 192 ASIA-PACIFIC TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 193 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 194 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 195 JAPAN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 196 JAPAN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 197 JAPAN DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 198 JAPAN PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 199 JAPAN SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 200 JAPAN TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 201 JAPAN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 202 JAPAN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 203 CHINA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 204 CHINA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 205 CHINA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 206 CHINA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 207 CHINA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 208 CHINA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 209 CHINA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 210 CHINA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 211 INDIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 212 INDIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 213 INDIA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 214 INDIA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 215 INDIA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 216 INDIA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 217 INDIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 218 INDIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 219 AUSTRALIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 220 AUSTRALIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 221 AUSTRALIA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 222 AUSTRALIA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 223 AUSTRALIA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 224 AUSTRALIA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 225 AUSTRALIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 226 AUSTRALIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 227 SINGAPORE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 228 SINGAPORE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 229 SINGAPORE DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 230 SINGAPORE PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 231 SINGAPORE SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 232 SINGAPORE TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 233 SINGAPORE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 234 SINGAPORE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 235 SOUTH KOREA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 236 SOUTH KOREA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 237 SOUTH KOREA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 238 SOUTH KOREA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 239 SOUTH KOREA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 240 SOUTH KOREA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 241 SOUTH KOREA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 242 SOUTH KOREA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 243 MALAYSIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 244 MALAYSIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 245 MALAYSIA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 246 MALAYSIA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 247 MALAYSIA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 248 MALAYSIA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 249 MALAYSIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 250 MALAYSIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 251 THAILAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 252 THAILAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 253 THAILAND DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 254 THAILAND PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 255 THAILAND SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 256 THAILAND TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 257 THAILAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 258 THAILAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 259 INDONESIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 260 INDONESIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 261 INDONESIA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 262 INDONESIA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 263 INDONESIA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 264 INDONESIA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 265 INDONESIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 266 INDONESIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 267 PHILIPPINES PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 268 PHILIPPINES PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 269 PHILIPPINES DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 270 PHILIPPINES PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 271 PHILIPPINES SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 272 PHILIPPINES TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 273 PHILIPPINES PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 274 PHILIPPINES PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 275 VIETNAM PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 276 VIETNAM PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 277 VIETNAM DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 278 VIETNAM PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 279 VIETNAM SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 280 VIETNAM TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 281 VIETNAM PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 282 VIETNAM PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 283 REST OF ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 284 SOUTH AMERICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 285 SOUTH AMERICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 286 SOUTH AMERICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 287 SOUTH AMERICA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 288 SOUTH AMERICA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 289 SOUTH AMERICA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 290 SOUTH AMERICA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 291 SOUTH AMERICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 292 SOUTH AMERICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 293 BRAZIL PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 294 BRAZIL PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 295 BRAZIL DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 296 BRAZIL PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 297 BRAZIL SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 298 BRAZIL TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 299 BRAZIL PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 300 BRAZIL PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 301 ARGENTINA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 302 ARGENTINA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 303 ARGENTINA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 304 ARGENTINA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 305 ARGENTINA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 306 ARGENTINA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 307 ARGENTINA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 308 ARGENTINA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 309 PERU PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 310 PERU PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 311 PERU DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 312 PERU PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 313 PERU SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 314 PERU TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 315 PERU PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 316 PERU PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 317 REST OF SOUTH AMERICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 318 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 319 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 320 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 321 MIDDLE EAST AND AFRICA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 322 MIDDLE EAST AND AFRICA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 323 MIDDLE EAST AND AFRICA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 324 MIDDLE EAST AND AFRICA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 325 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 326 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 327 SOUTH AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 328 SOUTH AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 329 SOUTH AFRICA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 330 SOUTH AFRICA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 331 SOUTH AFRICA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 332 SOUTH AFRICA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 333 SOUTH AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 334 SOUTH AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 335 EGYPT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 336 EGYPT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 337 EGYPT DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 338 EGYPT PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 339 EGYPT SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 340 EGYPT TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 341 EGYPT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 342 EGYPT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 343 SAUDI ARABIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 344 SAUDI ARABIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 345 SAUDI ARABIA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 346 SAUDI ARABIA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 347 SAUDI ARABIA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 348 SAUDI ARABIA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 349 SAUDI ARABIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 350 SAUDI ARABIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 351 ISRAEL PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 352 ISRAEL PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 353 ISRAEL DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 354 ISRAEL PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 355 ISRAEL SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 356 ISRAEL TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 357 ISRAEL PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 358 ISRAEL PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 359 UAE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 360 UAE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 361 UAE DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 362 UAE PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 363 UAE SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 364 UAE TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 365 UAE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 366 UAE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 367 KUWAIT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 368 KUWAIT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 369 KUWAIT DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 370 KUWAIT PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 371 KUWAIT SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 372 KUWAIT TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 373 KUWAIT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 374 KUWAIT PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 375 REST OF MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The Primary Angle-Closure Glaucoma Market is projected to grow at a CAGR of 6.1% during the forecast period by 2028.
The future market value of the Primary Angle-Closure Glaucoma Market is expected to reach USD 340.82 million by 2028.
The major players in the Primary Angle-Closure Glaucoma Market are Johnson & Johnson Vision Care, Inc. (a subsidiary of Johnson & Johnson Services Inc.), Aurolab, New World Medical, Inc., Sight Sciences, Inc., NIDEK CO., LTD, BVI, MicroSurgical Technology, etc.
The countries covered in the Primary Angle-Closure Glaucoma Market are U.S., Canada, Mexico, Germany, France, Italy U.K., Spain, Russia, Austria, Netherlands, Hungary, Poland, Switzerland, Turkey, Norway, Lithuania, Ireland, rest of Europe, Japan, etc.

BROWSE RELATED REPORTS

Europe Primary Angle-Closure Glaucoma Market – Industry Trends and Forecast to 2028
Asia-Pacific Primary Angle-Closure Glaucoma Market – Industry Trends and Forecast to 2028
Middle East and Africa Primary Angle-Closure Glaucoma Market – Industry Trends and Forecast to 2028
North America Primary Angle-Closure Glaucoma Market – Industry Trends and Forecast to 2028

BROWSE RELATED Blogs

Global Primary Angle-Closure Glaucoma Market is Expected to Grow at 6.1% in the Forecast Period of 2021 to 2028
North America Primary Angle Closure Glaucoma Market is Expected to Grow at 5.7% in the Forecast Period of 2021 to 2028

BROWSE RELATED Press Release

Rising Geriatric Population Base All Around the Globe is a Major Factor Fostering the Growth of the Primary Angle-Closure Glaucoma Market
Johnson & Johnson Vision Care, Inc. (A Subsidiary of Johnson & Johnson Services Inc.), Bausch & Lomb Incorporated (A Subsidiary of Bausch Health Companies Inc.) and ZEISS International are Dominating the North America Primary Angle-Closure Glaucoma Market in 2021
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Can be used by entire organization across the globe + Downloadable and Printable PDF + 30 + Countries

Buy Now
Request for TOC Speak to Analyst Inquire Before Buying Free Sample Report
Advance Formative Research Customization Request for bulk Reports

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials

David Manning - Thermo Fisher Scientific
Director, Global Strategic Accounts,

Dear Ricky,
I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice. Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough. Your work is much appreciated.

Image
Manager - Market Analytics,
Uriah D. Avila - Zeus Polymer Solutions

Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.

Business Development Manager,
(Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC

DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.

Image
Business Intelligence and Analytics,
Ipsen Biopharm Limited

We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.

Image
Competition Analyst,
Basler Web

I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.

Image
Marketing Director,
Buhler Group

It was indeed a good experience, would definitely recommend and come back for future prospects.

COO,
A global leader providing Drug Delivery Services

DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.

Image
Marketing Director,
Philips Healthcare

The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.

Image
Product manager,
Fujifilms

Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

Image
Investor relations,
GE Healthcare

Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.

Image
Market Analyst,
Medincell

We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.

Image
Andrew - Senior Global Marketing Manager,
Medtronic (US)

I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.

Image
Amarildo - Manager, Global Strategic Alignment
MasterCard

We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.

Image
Tor Hammer
Green Nexus LLc

Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects

Tommaso Finocchiaro
Market Intelligence Specialist Nippon Gasses

I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying. Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.

Yuki Kopyl (Asian Business Development Department)
UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future

Reports

Market Insights

Support

Solutions

DMCA Protected © DataBridge - All Rights Reserved. Payment

Suggested Searches